Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine. / Risum, Signe; Knigge, Ulrich; Langer, Seppo W.

In: Clinical Case Reports, Vol. 5, No. 12, 12.2017, p. 2085-2087.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Risum, S, Knigge, U & Langer, SW 2017, 'Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine', Clinical Case Reports, vol. 5, no. 12, pp. 2085-2087. https://doi.org/10.1002/ccr3.1262

APA

Risum, S., Knigge, U., & Langer, S. W. (2017). Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine. Clinical Case Reports, 5(12), 2085-2087. https://doi.org/10.1002/ccr3.1262

Vancouver

Risum S, Knigge U, Langer SW. Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine. Clinical Case Reports. 2017 Dec;5(12):2085-2087. https://doi.org/10.1002/ccr3.1262

Author

Risum, Signe ; Knigge, Ulrich ; Langer, Seppo W. / Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine. In: Clinical Case Reports. 2017 ; Vol. 5, No. 12. pp. 2085-2087.

Bibtex

@article{8bf08b9122b44e1794f7908f864878eb,
title = "Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine",
abstract = "Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.",
author = "Signe Risum and Ulrich Knigge and Langer, {Seppo W}",
year = "2017",
month = dec,
doi = "10.1002/ccr3.1262",
language = "English",
volume = "5",
pages = "2085--2087",
journal = "Clinical Case Reports",
issn = "2050-0904",
publisher = "JohnWiley & Sons Ltd",
number = "12",

}

RIS

TY - JOUR

T1 - Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

AU - Risum, Signe

AU - Knigge, Ulrich

AU - Langer, Seppo W

PY - 2017/12

Y1 - 2017/12

N2 - Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

AB - Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

U2 - 10.1002/ccr3.1262

DO - 10.1002/ccr3.1262

M3 - Journal article

C2 - 29225862

VL - 5

SP - 2085

EP - 2087

JO - Clinical Case Reports

JF - Clinical Case Reports

SN - 2050-0904

IS - 12

ER -

ID: 196371326